Cargando…

Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden

The Janus kinase (JAK)–STAT signaling pathway is relevant in both Takayasu and giant cell arteritis (GCA), and the use of JAK inhibitors (JAKi) in arthritis, psoriasis, and inflammatory bowel disease is nowadays common. Some evidence of the clinical efficacy of JAKi in GCA exists and a phase III ran...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eriksson, Per, Skoglund, Oliver, Hemgren, Cecilia, Sjöwall, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247956/ https://www.ncbi.nlm.nih.gov/pubmed/37304255 http://dx.doi.org/10.3389/fimmu.2023.1187584

Ejemplares similares

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

The Diagnostic Performance of an Extended Ultrasound Protocol in Patients With Clinically Suspected Giant Cell Arteritis
por: Skoog, Johan, et al.
Publicado: (2022)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib
por: Yamamura, Yuriko, et al.
Publicado: (2019)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China
por: Li, Wendao, et al.
Publicado: (2022)

Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study
por: Walhelm, Tomas, et al.
Publicado: (2021)

Innate and Adaptive Immunity in Giant Cell Arteritis
por: Akiyama, Mitsuhiro, et al.
Publicado: (2021)

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
por: Kubo, Satoshi, et al.
Publicado: (2018)

The Treatment of Giant Cell Arteritis in Different Clinical Settings
por: Pfeil, Alexander, et al.
Publicado: (2019)

The Immunopathology of Giant Cell Arteritis Across Disease Spectra
por: Robinette, Michelle L., et al.
Publicado: (2021)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
por: Quadri, Iman, et al.
Publicado: (2023)

Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis
por: Rondaan, Christien, et al.
Publicado: (2017)

Familial risks between giant cell arteritis and Takayasu arteritis and other autoimmune diseases in the population of Sweden
por: Thomsen, Hauke, et al.
Publicado: (2020)

Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies
por: Hammitzsch, Ariane, et al.
Publicado: (2020)

Targeting the Janus Kinase Family in Autoimmune Skin Diseases
por: Howell, Michael D., et al.
Publicado: (2019)

Affected Microcirculation and Vascular Hemodynamics in Takayasu Arteritis
por: Svensson, Christina, et al.
Publicado: (2022)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Molecular dissection of Janus kinases as drug targets for inflammatory diseases
por: Kwon, Sunghark
Publicado: (2022)

Fighting Fatigue in Systemic Lupus Erythematosus: Experience of Dehydroepiandrosterone on Clinical Parameters and Patient-Reported Outcomes
por: Skoglund, Oliver, et al.
Publicado: (2022)

Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
por: Reitsema, Rosanne D., et al.
Publicado: (2023)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors
por: Matsumoto, Kotaro, et al.
Publicado: (2023)

Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2019)

A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
por: Lee, Sang-Doo, et al.
Publicado: (2022)

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
por: Rajasimhan, Suraj, et al.
Publicado: (2020)

Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
por: Papierzewska, Małgorzata, et al.
Publicado: (2023)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis
por: Samson, Maxime, et al.
Publicado: (2023)

Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients
por: van Nieuwland, Marieke, et al.
Publicado: (2023)

Use of high-plex data provides novel insights into the temporal artery processes of giant cell arteritis
por: Parreau, Simon, et al.
Publicado: (2023)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Giant Cell Arteritis
por: Coulier, Bruno, et al.
Publicado: (2018)

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals
por: Melikhov, Oleg, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lv3q559q11a6f3hdcigei14hqa